Talavera A, Año G, García H, Moreira T, Delgado H, Riverón L, Gil S, Miranda A, Cedré B, Valmaseda T, Pino Y, Pérez J L, Infante J F, García L, Sierra G
Finlay Institute, 27 Ave, # 19805 La Lisa, Ciudad de la Habana, A.P. 16017, Cod. 11600, Cuba.
Vaccine. 2006 May 1;24(18):3746-9. doi: 10.1016/j.vaccine.2005.07.015. Epub 2005 Aug 8.
Genetically modified Vibrio cholerae strain 638 (biotype El Tor, serotype Ogawa) has previously been shown to be immunogenic in animal models and in human trials. Our objective in the work reported herein was to describe the process development methods for the production of the 638 attenuated cholera vaccine. Cell seed bank, culture of biomass, lyophilization and final formulation were processes were developed. The results show kinetics of culture that fulfils a logistical model. The microbiological properties, colonizing capability, immunogenicity and non-toxigenicity of the final product were indistinguishable from the properties of the working seed lot. We conclude that the non-reactogenic, immunogenic and protective strain 638 is robust and can withstand the fermentation processes required for large-scale production of a vaccine.
